Trans activists and unregulated clinics have sought to pressure GPs into illegally prescribing puberty blockers, the NHS has ...

Whenever a new drug goes into the first stages of clinical trial, there are certain groups of people that are excluded from ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global ...

“Both mindfulness and cognitive behavioral therapy were shown to be safe, effective treatments, providing lasting benefits ...

Explore graduate programs at Nova Southeastern University (Clinical Psy.D.) ...

Alzheimer’s blood tests may one day allow patients and their doctors to track their individual progress in reducing risk, ...

LVS Advisory, a New York City-based full-service investment firm, recently released its first-quarter 2025 investor letter. A ...

Credit: MUNGKHOOD STUDIO/Shutterstock. Clinical research organisation (CRO) ICON has begun the integration of Medidata Clinical Data Studio into its clinical studies. This development makes ICON the ...

“ICON leads in risk-based quality management, integrating Data Management and Central Monitoring teams in our Clinical Data Science group. To meet growing data demands and customer expectations ...

Adoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts NEW YORK, March 20, 2025 ...

The integration of Clinical Data Studio into ICON’s service offerings helps unlock the full potential of the Medidata Data Experience, merging information from both Medidata and non-Medidata sources, ...